Coronado Biosciences, Inc. (CNDO)

[JT460]

NEW YORK (TheStreet) -- Coronado Biosciences Inc (CNDO_) exploded on news its pilot study of an oral drug to treat autism was successful. The micro-cap had added 27.5% to $2.27 by early afternoon of Friday's session.

The clinical trial studied the effect of CNDO-201 over a placebo in autistic patients and found a statistically-significant difference in favor of the Coronado-developed treatment.
"There is increasing evidence that immune dysregulation plays an important role in this developmental disorder and we are encouraged by the interim data from this pilot study," said CEO Dr. Harlan F. Weisman in a statement.

http://www.thestreet.com/story/12154820/1/two-biopharmaceutical-companies-moving-markets-on-friday.html